Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365203 | 0.86 | P2RX7 (0.56) | P2RX7ALDH1A1L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL30090979 | 0.85 | L3MBTL1 (0.56) | P2RX7ALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL18111428 | 0.82 | HSD11B1 (0.71) | HSD11B1P2RX7ALDH1A1CACNA1GL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL5371514 | 0.81 | ALDH1A1 (0.42) | P2RX7ALDH1A1L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL18110612 | 0.78 | TDP1 (0.49) | P2RX7ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL12614285 | 0.75 | SLC6A3 (0.45) | HSD11B1P2RX7CACNA1GICMTSLC6A4 | |
| SCHEMBL4699181 | 0.75 | TACR1 (0.48) | HSD11B1 | |
| SCHEMBL14711534 | 0.74 | HPGD (0.47) | HSD11B1ALDH1A1L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL15897753 | 0.74 | POLB (0.48) | HSD11B1P2RX7ALDH1A1L3MBTL1POLB | |
| SCHEMBL14794814 | 0.74 | OPRM1 (0.40) | HSD11B1P2RX7ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| EP-3277670-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277671-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277672-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016161286-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161279-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161269-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | HSD11B1 916/4885P2RX7 2411/4885ALDH1A1 707/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | HSD11B1 916/4885P2RX7 2411/4885ALDH1A1 707/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | HSD11B1 296/4885P2RX7 2716/4885ALDH1A1 263/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | HSD11B1 296/4885P2RX7 2716/4885ALDH1A1 263/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | HSD11B1 296/4885P2RX7 2716/4885ALDH1A1 263/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | HSD11B1 916/4885P2RX7 2411/4885ALDH1A1 707/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | HSD11B1 296/4885P2RX7 2716/4885ALDH1A1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.